Dapsone

證據等級: L5

預測適應症: 1 個

Dapsone: From Leprosy to Pneumocystosis

One-Sentence Summary

Dapsone is a diaminodiphenyl sulfone antimicrobial agent, historically used as the cornerstone treatment for leprosy and inflammatory dermatological conditions such as dermatitis herpetiformis. The TxGNN model predicts it may be effective for Pneumocystosis (Pneumocystis jirovecii pneumonia, PJP), with 14 clinical trials and 19 publications currently supporting this direction — and notably, this prediction recapitulates an already internationally-validated secondary indication, confirming strong model accuracy.

Quick Overview

Item	Content
Original Indication	Leprosy; dermatitis herpetiformis (established medical use; no Philippines registration on file)
Predicted New Indication	Pneumocystosis (Pneumocystis jirovecii pneumonia)
TxGNN Prediction Score	99.73%
Evidence Level	L1
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data from DrugBank was not available for this report. Based on published pharmacological literature within this evidence pack, however, Dapsone — a diaminodiphenyl sulfone (DDS) compound — acts by competitively inhibiting dihydropteroate synthase (DHPS), the enzyme that catalyzes folate biosynthesis. This is the same mechanism underpinning its activity against Mycobacterium leprae (leprosy). Because Pneumocystis jirovecii, the causative fungal pathogen of pneumocystosis, cannot scavenge exogenous folate and relies entirely on de novo synthesis, it is directly and highly sensitive to DHPS inhibition. When Dapsone is co-administered with trimethoprim (a DHFR inhibitor), the combination achieves dual-point blockade of the folate pathway, producing a well-characterised synergistic anti-Pneumocystis effect.

The mechanistic bridge from leprosy to pneumocystosis is therefore straightforward: both pathogens share obligate dependence on folate biosynthesis, making Dapsone’s core mechanism directly transferable across these biologically distinct infectious disease states. The TxGNN knowledge-graph score of 0.9973 reflects a strong edge chain — Dapsone → antimicrobial/antiprotozoal activity → folate metabolism inhibition → P. jirovecii — fully consistent with known pharmacology.

Crucially, this is not a speculative repurposing. Dapsone is already included as a first-line alternative prophylactic agent in the ECIL-5 evidence-based guidelines for PCP prevention in patients with haematological malignancies and HSCT recipients (Grade A-II recommendation), and is endorsed by the IDSA for HIV-associated PCP prophylaxis when TMP-SMX is not tolerated. Multiple large Phase 3 RCTs conducted through the AIDS Clinical Trials Group (ACTG) in the 1990s established its efficacy for both treatment and primary/secondary prophylaxis. TxGNN has accurately reproduced a validated clinical reality — which is the strongest possible validation of the model’s predictive value.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00000802	Phase 3	Completed	700	Head-to-head RCT comparing daily Dapsone vs Atovaquone for PCP prophylaxis in HIV patients (CD4 ≤200/mm³) intolerant to TMP/SMX; large-scale, directly relevant efficacy trial
NCT00000640	Phase 3	Completed	290	Dapsone/Trimethoprim vs Clindamycin/Primaquine vs TMP-SMX for treatment of mild-to-moderate PCP in AIDS; established Dapsone/TMP as effective oral treatment alternative
NCT00000991	Phase 3	Completed	600	Compared three anti-PCP prophylaxis regimens (including Dapsone) plus AZT for primary prevention in advanced HIV; also assessed protection against toxoplasmosis
NCT00001028	Phase 3	Completed	400	Dapsone (three times weekly) vs aerosolized pentamidine for PCP prophylaxis in TMP/SMX-intolerant HIV patients; confirmed Dapsone dosing schedule and comparative efficacy
NCT00002283	N/A	Completed	N/A	Randomized prospective study comparing Dapsone + trimethoprim vs TMP-SMX for first-episode PCP in AIDS patients; evaluated outpatient treatment suitability and adverse event rates
NCT02550080	Phase 4	Unknown	3,130	Prospective HLA-B*1301 genetic pre-screening study to reduce Dapsone Hypersensitivity Syndrome (DHS) incidence; large-scale real-world safety study spanning multiple Dapsone indications including PJP
NCT00002120	Phase 1	Completed	20	Explored Trimetrexate + Dapsone + leucovorin vs TMP-SMX for moderately severe PCP in AIDS; characterised pharmacokinetics and established early safety profile of combination
NCT00000739	Phase 1	Completed	96	Daily vs weekly oral Dapsone for PCP prophylaxis in HIV-infected infants and children; generated paediatric pharmacokinetic data and dosing guidance
NCT00141037	Phase 1/2	Completed	130	Steroid-free immunosuppression in paediatric renal transplant; Dapsone used as routine PCP prophylaxis component, providing real-world safety context in non-HIV immunocompromised children
NCT04328688	N/A	Completed	30	Clindamycin–TMP/SMX for PCP after solid organ transplantation; Dapsone referenced as established second-line alternative, supporting its role across immunocompromised populations beyond HIV

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38583518	2024	Systematic Review / Network Meta-analysis	Clinical Microbiology and Infection	Network meta-analysis of RCTs comparing all PCP prophylaxis regimens (TMP-SMX, Dapsone-based, pentamidine, atovaquone) in people living with HIV; provides the most current quantitative comparative efficacy and safety estimates
39732393	2025	Systematic Review / Network Meta-analysis	Clinical Microbiology and Infection	Network meta-analysis of RCTs evaluating PCP treatment regimens in PLHIV; synthesises contemporary evidence including Dapsone-containing combinations
27550992	2016	Clinical Practice Guideline	Journal of Antimicrobial Chemotherapy	ECIL-5 evidence-based recommendations for PCP prophylaxis in haematological malignancies and HSCT; Dapsone recommended as first-line alternative to TMP-SMX (Grade A-II)
9675476	1998	Review	Clinical Infectious Diseases	Authoritative review of Dapsone for PCP prevention and treatment; covers DHPS inhibition mechanism, oral bioavailability (70–80%), PK/PD profile in alveolar fluid, and synergistic activity with trimethoprim
33870843	2021	Narrative Review	Expert Opinion on Pharmacotherapy	Updated comprehensive review of PJP prevention and treatment across all immunocompromised host categories; practical drug selection guidance including Dapsone regimens
11155588	2001	Pharmacological Review	Dermatologic Clinics	Dual overview of Dapsone and sulfapyridine mechanisms; confirms Dapsone as the most important anti-leprosy drug and key PCP prophylaxis agent in HIV disease
8605054	1995	Comparative Clinical Study	AIDS (London)	Three-arm study comparing aerosolized pentamidine, cotrimoxazole, and Dapsone-pyrimethamine for primary PCP prophylaxis; assessed efficacy, toxoplasmosis prevention, and survival
9606476	1998	Safety Case Series	Annals of Pharmacotherapy	Methemoglobinemia in a patient receiving Dapsone for PCP prophylaxis; documents this clinically important adverse effect and the need for haemoglobin monitoring
32714715	2020	Case Report	Cureus	Dapsone-induced hypoxia via methemoglobinemia; reinforces the necessity of SpO₂ monitoring and clinical awareness of this rare but serious complication during Dapsone therapy
18971152	2008	Narrative Review	Journal of the Formosan Medical Association	Taiwan-focused review of PJP pathophysiology, reclassification of the organism as a fungus, diagnosis, and treatment; provides Asia-Pacific regional clinical context

Philippines Market Information

Dapsone currently has no registered drug products with the Philippines FDA. There are no authorization numbers, brand names, or approved indications on file.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	No registrations found	—	—

Should clinical deployment be considered, a Philippines FDA registration pathway (new drug application, or a special access / compassionate use mechanism) would be a prerequisite before institutional use.

Safety Considerations

Package insert safety data (local warnings and contraindications) were not available in this evidence pack.

Please refer to the package insert for safety information.

Two additional safety signals are well-documented in the literature included in this evidence pack and warrant proactive clinical attention:

Methemoglobinemia: Dapsone can oxidize haemoglobin to methaemoglobin, causing dose-dependent cyanosis and hypoxia. Baseline G6PD screening and periodic SpO₂/methaemoglobin monitoring are strongly advised (PMID 9606476, 32714715).
Dapsone Hypersensitivity Syndrome (DHS): Strongly associated with the HLA-B*1301 allele (prevalent in Asian populations). Prospective genetic pre-screening has been studied in a large Phase 4 trial (NCT02550080, n=3,130) and may substantially reduce DHS incidence.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The evidence base for Dapsone in pneumocystosis is exceptionally strong — four completed Phase 3 RCTs (total n>1,900), two recent systematic reviews with network meta-analyses, and explicit guideline endorsement at Grade A-II (ECIL-5). The primary barrier to deployment in the Philippines is not evidence strength, but the absence of local market registration and the need for a formal safety monitoring plan.

To proceed, the following is needed:

Establish a Philippines FDA registration or special access pathway for Dapsone
Obtain and review the local package insert to document full warnings, contraindications, and drug interactions
Implement a methemoglobinemia monitoring protocol: baseline G6PD screen, then periodic SpO₂ and methaemoglobin assessment during therapy
Evaluate feasibility of HLA-B*1301 pre-screening given high allele frequency in Filipino and Southeast Asian populations, to mitigate Dapsone Hypersensitivity Syndrome risk
Define the target patient population (HIV/AIDS with CD4 <200/mm³; solid organ transplant; haematological malignancy/HSCT) and select the appropriate prophylaxis or treatment dosing regimen accordingly
Complete a formal drug interaction review, particularly with trimethoprim (combination partner), rifampicin, and antiretrovirals commonly co-administered in HIV management
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.